← Back to patent-cliff list
TM-471-1
Tier C — Watch / tradeTM-471-1
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：BTK
Indications (approved)：脑炎, Multiple sclerosis, Marginal zone B-cell lymphoma, Chronic urticaria, Nephropathy, 自身免疫疾病, B-cell lymphoma
Regional status
US
-
EU
-
China
Phase II
2025-12-12
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of TM-471-1?
Approved indications include: 脑炎, Multiple sclerosis, Marginal zone B-cell lymphoma, Chronic urticaria, Nephropathy, 自身免疫疾病, B-cell lymphoma.
When does the TM-471-1 patent expire?
No public expiry year is available for TM-471-1 yet; this page updates once verified.
How do I get a quote for TM-471-1 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29